313 related articles for article (PubMed ID: 27044555)
1. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY
Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
4. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
6. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
8. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
9. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
Su CF; Chuang C; Lin YT; Chan YJ; Lin JC; Lu PL; Huang CT; Wang JT; Chuang YC; Siu LK; Fung CP
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):651-659. PubMed ID: 29238934
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
[No Abstract] [Full Text] [Related]
12. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1.
Dong F; Zhang Y; Yao K; Lu J; Guo L; Lyu S; Yang Y; Wang Y; Zheng H; Song W; Liu G
Microb Drug Resist; 2018 Mar; 24(2):154-160. PubMed ID: 28594635
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.
Ariffin H; Navaratnam P; Mohamed M; Arasu A; Abdullah WA; Lee CL; Peng LH
Int J Infect Dis; 2000; 4(1):21-5. PubMed ID: 10689210
[TBL] [Abstract][Full Text] [Related]
15. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.
Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N
Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725
[TBL] [Abstract][Full Text] [Related]
16. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
[TBL] [Abstract][Full Text] [Related]
17. Bloodstream Infections due to Carbapenem-Resistant
Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Medeiros GS; Rigatto MH; Falci DR; Zavascki AP
Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of carbapenem-resistant
Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L
Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492
[TBL] [Abstract][Full Text] [Related]
20. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Cprek JB; Gallagher JC
Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
